Funding Arrangements - Additional Information (Details) - USD ($) $ in Thousands |
1 Months Ended | 3 Months Ended | 9 Months Ended | ||||
|---|---|---|---|---|---|---|---|
Jul. 31, 2024 |
Jun. 30, 2023 |
Apr. 30, 2021 |
Sep. 30, 2024 |
Sep. 30, 2023 |
Sep. 30, 2024 |
Sep. 30, 2023 |
|
| Funding Arrangement [Line Items] | |||||||
| Grant income | $ 292 | $ 1,640 | $ 812 | $ 4,759 | |||
| CARB-X Agreement | |||||||
| Funding Arrangement [Line Items] | |||||||
| Grant receivable on unreimbursed, eligible costs incurred | 300 | 300 | |||||
| CARB-X Agreement | Minimum | |||||||
| Funding Arrangement [Line Items] | |||||||
| Potential funding committed by award | 11,700 | 11,700 | |||||
| National Institutes Of Health | |||||||
| Funding Arrangement [Line Items] | |||||||
| Potential funding amount of award to develop vaccine to prevent shingella infections | $ 9,500 | $ 4,600 | $ 500 | ||||
| National Institutes Of Health | Maximum | |||||||
| Funding Arrangement [Line Items] | |||||||
| Potential funding period of award to develop vaccine to prevent shingella infections | 5 years | 5 years | 5 years | ||||
| Cost Reimbursement Sub-Award Agreement | |||||||
| Funding Arrangement [Line Items] | |||||||
| Grant income | $ 300 | $ 1,600 | $ 800 | $ 4,800 | |||